Sanofi-aventis Groupe acquired Provention Bio, Inc., to provide best-in-class medications, and to provide those at risk of developing Stage 3 type 1 diabetes with life-changing advantages. Further, the acquisition also advances the company's strategy to move towards pharmaceuticals with distinctive profiles.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?